Oxford Drug Design secures £2.2m Series A investment and grant backing to advance drug discovery programmes.
The biotechnology spin-out raised funds from backers including the Angel CoFund and o2h Ventures alongside Department of Health and Social Care grants.
Oxford Drug Design is a biotechnology company that uses a proprietary computational and machine learning platform to discover small-molecule drugs for oncology. The firm originated as a spinout from Oxford University.
Oxford Drug Design has secured £2.2m in a Series A funding round supported by the Angel CoFund, o2h Ventures, and the Department of Health and Social Care. The capital combines equity investment with grant funding from the UK-China research competition.
The proceeds will be directed towards advancing the company's drug research and discovery efforts, including a specific project tackling anti-microbial resistance in partnership with academic and international institutions.
This latest injection contributes to a broader funding total for the year, bringing the firm's aggregate equity and grant intake in 2019 to over £9m.
From the founder
"This latest funding further validates our computational design-led focus that has enabled rapid progress in building our pipeline of novel antibiotic programmes."
Paul Finn
CEO at Oxford Drug Design
Investor perspective
"The team at Oxford Drug Design are advancing swiftly with their programme, and winning major international funding and attracting private equity funding provide strong validation of the work they are undertaking. Antimicrobial resistance is a growing issue for the global healthcare system which only a small number of innovative companies are working to solve, so we are delighted to support ODD’s pioneering efforts."
Tim Mills
managing partner, Angel CoFund
Use of funds
- 01Fund research and development
Investors
Categories
About the company
Oxford Drug Design
Oxford Drug Design develops novel cancer therapeutics using a proprietary computational and machine learning platform.